Recombinant Human Activin A Protein (GMP Grade)
Catalog Number： PM112-01
Price：Please inquire first
Product Details
Activin A is a homodimer composed of two inhibin β subunits linked by disulfide bonds. It activates intracellular signaling pathways through specific receptors and plays a critical role in various biological processes, including cell growth, differentiation, apoptosis, and tissue repair [1]. By binding to type I and type II activin receptors, Activin A activates the SMAD-dependent signaling pathway, thereby regulating the expression of target genes. This signaling process is essential for a wide range of cellular functions and developmental events [2–3]. Activin A is involved in the pathogenesis of various diseases, including the progression of certain cancers, autoimmune disorders, and tissue fibrosis. Due to its regulatory functions, Activin A has emerged as a potential therapeutic target, particularly in promoting wound healing, enhancing immune function, and cancer therapy [4–6].
[1] Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000 Apr 21;103(4):295-309.
[2] Chen Y G, Wang Q, Lin S L, et al. Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis. Experimental biology and medicine, 2006, 231(5): 534-544.
[3] Harrison C A, Gray P C, Vale W W, et al. Antagonists of activin signaling: mechanisms and potential biological applications. Trends in Endocrinology & Metabolism, 2005, 16(2): 73-78.
[4] Ghorbani-Dalini S, Azarpira N, Sangtarash M H, et al. Optimization of activin-A: a breakthrough in differentiation of human induced pluripotent stem cell into definitive endoderm. 3 Biotech, 2020, 10(5): 215.
[5] Mennen R H, Oldenburger M M, Piersma A H. Endoderm and mesoderm derivatives in embryonic stem cell differentiation and their use in developmental toxicity testing. Reproductive Toxicology, 2022, 107: 44-59.
[6] Ries A, Schelch K, Falch D, et al. Activin A: an emerging target for improving cancer treatment?. Expert Opinion on Therapeutic Targets, 2020, 24(10): 985-996.
